Up next

Company Executives Outline Growth Strategies and Expansions at the DCAT Member Company Announcement Forum

In this special issue of DCAT Value Chain Insights, we are providing information that would have been presented at the DCAT Member Company Announcement Forum at DCAT Week ’20. Originally scheduled to be held on March 23 in New York, these announcements were selected by the Announcement Oversight Task Force, as they present the latest major company news impacting the pharmaceutical manufacturing value chain. CEOs and senior executives from DCAT member companies outline their companies’ growth strategies by providing updates on key mergers and acquisitions and expansions with news from the following companies: Cambrex, Recipharm, Thermo Fisher Scientific, Lonza, SK pharmteco, Catalent, Biocon, CordenPharma, and WuXi STA. The individual news developments are outlined below.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

CDMO Moves: Lonza Increasing Position in US

By
Lonza is increasing its position in the US with a pending acquisition of five CDMO sites from the life-sciences business of Merck KGaA. What sites and capabilities is the company gaining in the deal?

Orphan Drugs: The Top Products & Companies

By
Orphan drug sales are projected to reach a peak of 30% of the global prescription drug market by 2027 and sales of $400 billion by 2032. What products and companies are leading growth?

Anthropic & Pharma: What Comes Next

By
In what is projected to be one of the largest IPOs in history, the AI giant, Anthropic, has taken the first step in holding an IPO, with AI in bio/pharmaceutical development a key component in its growth strategy.

Indian Pharma Companies & Innovator Drugs

By
Sun Pharma’s pending $11.75-billion acquisition of Organon was one of the largest M&A in 2026 and is aligned with its strategy of in part diversifying into innovator drugs, a step taken by other Indian companies.